Emendo Biotherapeutics
Last updated: August 04, 2025
David Baram - President & CEO
Country: USA | Funding: $317.8M (+) | Add Funding
Website: http://emendobio.com/
Emendo Biotherapeutics develops gene editing platform to expand the list of diseases amenable to treatment with gene editing, resulting in a pipeline of hematology and ophthalmology programs.
Website: http://emendobio.com/
Emendo Biotherapeutics develops gene editing platform to expand the list of diseases amenable to treatment with gene editing, resulting in a pipeline of hematology and ophthalmology programs.
